• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Castle Biosciences, Inc. - Common stock (NQ:CSTL)

28.00 +1.21 (+4.52%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 31, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Castle Biosciences, Inc. - Common stock

< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
News headline image
Castle Biosciences Presents Data on DecisionDx®-Melanoma and DecisionDx®-SCC at SDPA Annual Summer Dermatology Conference 2021
July 22, 2021
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences Expands its Board of Directors with New Appointments
July 16, 2021
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Return On Capital Employed Overview: Castle Biosciences ↗
June 24, 2021
In Q1, Castle Biosciences (NASDAQ:CSTL) posted sales of $22.81 million. Earnings were up 41.29%, but Castle Biosciences still reported an overall loss of $4.28 million. Castle... 
Via Benzinga
News headline image
Castle Biosciences is Listed in the Houston Chronicle’s “CHRON 100” as One of the 100 Most Successful Publicly Traded Companies in Houston
June 21, 2021
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences Announces Receipt of New York Laboratory Permit
June 09, 2021
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Looking Into Castle Biosciences's Return On Capital Employed ↗
June 08, 2021
During Q1, Castle Biosciences's (NASDAQ:CSTL) reported sales totaled $22.81 million. Despite a 41.29% in earnings, the company posted a loss of $4.28 million. Castle Biosciences... 
Via Benzinga
News headline image
Castle Biosciences to Participate at the Baird 2021 Healthcare ESG Symposium
June 07, 2021
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences to Host Ribbon Cutting Ceremony at New Corporate Headquarters
May 24, 2021
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences Supports the American Skin Association with Research Grant
May 21, 2021
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Expert Panel Provides Framework for Incorporating DecisionDx-SCC Results Into Clinical Decision Making for Cutaneous Squamous Cell Carcinoma Patients With One or More Risk Factors
May 20, 2021
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences to Participate in the Oppenheimer MedTech, Tools, & Diagnostics Summit
May 19, 2021
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Cathie Wood Cuts Apple Stake Almost Entirely — And Buys More Coinbase ↗
May 18, 2021
Cathie Wood-led Ark Investment Management on Monday shed nearly all of its stake in Apple Inc (NASDAQ: 
Via Benzinga
News headline image
Tiffany Olson, Seasoned Diagnostics Executive, Joins Castle Biosciences’ Board of Directors
May 11, 2021
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences: Q1 Earnings Insights ↗
May 10, 2021
Shares of Castle Biosciences (NASDAQ:CSTL) were unchanged in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share decreased 666.67... 
Via Benzinga
News headline image
Castle Biosciences Announces First Quarter 2021 Results
May 10, 2021
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences Announces Pipeline Initiative to Develop Genomic Test Targeting Systemic Therapy Response in Patients with Psoriasis, Atopic Dermatitis and Related Conditions
May 10, 2021
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences Recognized for Skin Cancer Diagnostics Innovation in 2021 MedTech Breakthrough Awards Program
May 06, 2021
From Castle Biosciences, Inc.
Via Business Wire
News headline image
The Week Ahead In Biotech (May 9-15): Heron, Apellis FDA Decisions, Presentations and Earnings ↗
May 09, 2021
Biotech stocks came under pressure in the week ended May 7 as traders digested a slew of earnings news flow and a handful of clinical trial readouts. COVID-19 vaccine stocks came... 
Via Benzinga
News headline image
New Data Demonstrate that 99% of Surveyed Patients Diagnosed With Uveal Melanoma Gain Value From DecisionDx-UM Test
May 05, 2021
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences Collaborates With the Colorado Melanoma Foundation and Epiphany Dermatology to Provide Free Skin Cancer Screenings Across the Southwest U.S.
May 04, 2021
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences Supports American Academy of Dermatology's "Skin Cancer, Take a Hike!™" Steps Challenge for Skin Cancer Awareness Month
April 30, 2021
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences Signs Definitive Agreement to Acquire Myriad myPath® Laboratory
April 27, 2021
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences to Release First Quarter 2021 Financial Results, Provide Pipeline Update and Host Conference Call on Monday, May 10, 2021
April 26, 2021
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences Presents Data Demonstrating DecisionDx-Melanoma as Significant, Independent Predictor of Recurrence in Stage I Cutaneous Melanoma Population
April 23, 2021
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences Presents Data at the Dermatology Nurses’ Association 2021 Annual Convention
April 22, 2021
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences Presents Data at the 10th World Congress of Melanoma and 17th European Association of Dermato-Oncology Congress
April 16, 2021
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Late-Breaking New Independent Validation Study of 1,674 Patients Demonstrates Castle Biosciences' i31-GEP Artificial Intelligence Algorithm Improves Precision of Sentinel Lymph Node Positivity Prediction in Cutaneous Melanoma
April 15, 2021
From Castle Biosciences
Via Business Wire
News headline image
Largest, Independent, Prospective Study Demonstrates Utility of DecisionDx®-Melanoma for Prediction of Outcomes in Patients With Cutaneous Melanoma Referred for Sentinel Node Biopsy
April 14, 2021
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences Announces Prospective, Multi-Center Publication Demonstrating DecisionDx®-Melanoma as Significant, Independent Predictor of Patient Outcomes in Cutaneous Melanoma
April 13, 2021
From Castle Biosciences, Inc.
Via Business Wire
< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap